Background: Venous ablation (VA) of the saphenous vein is the most common procedure performed for venous insufficiency. The incidence of concomitant deep venous reflux (DVR) in patients undergoing VA is unknown. Our hypothesis is that patients undergoing saphenous VA with concomitant DVR exhibit a higher clinical, etiology, anatomy, and pathophysiology (CEAP) stage and less relief after VA compared to patients without DVR.
Methods: Electronic medical records of patients treated with saphenous VA at a tertiary care center from March 2012 to June 2016 were reviewed. Patients were divided into 2 groups based on presence or absence of DVR on initial ultrasound (US) before saphenous VA. Patient characteristics and outcomes were compared. A telephone survey was conducted to assess long-term symptomatic relief, compliance with compression, and pain medication use. Subgroup analysis of patients with post-thrombotic versus primary DVR was performed.
Results: 362 patients underwent 497 ablations, and the incidence of DVR (>1 sec) was 20% (N = 71). Patients with DVR were significantly more likely to be male (46.4% vs. 32.1%, P = 0.021) and of Black race (21.2% vs. 5.5%, P = 0.0001) compared to patients without DVR. Patients with DVR were more likely to have a history of deep vein thrombosis (DVT) (15.1% vs. 7.9%, P = 0.045), but there was no difference in other comorbidities. There was no significant difference in presenting symptoms, CEAP stage, or symptom severity based on numeric rating scale (NRS) (0-10) for pain and swelling. Clinical success of saphenous VA was comparable between the 2 groups, but patients with DVR were more likely to develop endovenous heat-induced thrombosis (EHIT) II-IV (6% vs. 1%, P = 0.002). After a mean follow-up of 26 months, there was still no difference in pain or swelling scores, but patients with DVR were more likely to use compression stockings and used them more frequently. Only 11 of 71 patients with DVR had a history of DVT. Patients with post-thrombotic DVR were significantly older than patients with primary DVR (67.3 vs. 57.2, P = 0.038) and exhibited a trend toward more advanced venous disease (C4-C6: 45.4% vs. 33.3%, P = 0.439).
Conclusions: In this study, 20% of patients undergoing saphenous VA demonstrated DVR, which was more common in Black men. Presence of DVR is associated with increased risk of EHIT after saphenous VA but does not seem to impact disease severity or clinical relief after ablation. Larger studies are needed to understand outcome differences between post-thrombotic and primary DVR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.avsg.2022.11.034 | DOI Listing |
Neurochirurgie
December 2024
Aix Marseille Univ, APM, UH Timone, Department of Neurosurgery, Marseille, France.
Background: The Da Vinci robot ® (DVR), released in the early 2000s, provided a set of innovation aiming at pushing minimally invasive surgery forward. Its stereoscopic magnified visualization camera, motions that exceed the natural range of the human hand, or tremor reduction enhanced the surgeon's skills and added value in many surgical fields.
Objective: To map the current use of the DVR in spine surgery, identify gaps, address its limits and future perspectives.
Heart Lung Circ
November 2024
Department of Cardiac Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address:
Aim: Mitral valve repair (MVr) is associated with more favourable long-term outcomes than mitral valve replacement (MVR) in cases of isolated mitral valve disease suitable for repair. However, there is debate regarding whether the superiority of MVr extends to patients with concomitant aortic and mitral valve disease. Therefore, this meta-analysis was conducted to compare the survival benefits between aortic valve replacement (AVR) plus MVr with a double valve replacement (DVR).
View Article and Find Full Text PDFN Engl J Med
October 2024
From the University of New South Wales, Sydney (V.P.); the Mayer IgA Nephropathy Laboratories, University of Leicester, Leicester, United Kingdom (J.B.); Ohio State University Wexner Medical Center, Columbus (B.R.); Kawasaki Medical School, Okayama, Japan (N.K.); AZ Delta, Roeselare, Belgium (B.M.); Peking University First Hospital, Beijing (H.Z.); Hospital Britanico, Buenos Aires (H.T.); Novartis Pharma, Basel, Switzerland (D.K., O.P., S.J.-S., T.M., N.G., R.R., T.H.); and the University of Alabama at Birmingham, Birmingham (D.V.R.).
Background: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway.
Methods: In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled adults with biopsy-confirmed IgA nephropathy and proteinuria (defined as a 24-hour urinary protein-to-creatinine ratio of ≥1 [with protein and creatinine both measured in grams]) despite optimized supportive therapy.
Indian J Nephrol
June 2024
Department of Medicine, Division of Nephrology, University of Alabama, Birmingham, USA.
Ann Card Anaesth
October 2024
Department of Reaseach, UN Mehta Hospital, Ahmedabad, Gujarat, India.
Aims And Objectives: The incidence of postoperative liver dysfunction is high in patients undergoing double-valve replacement - mitral and aortic valve replacement (DVR). This study aims to evaluate N-acetylcysteine's free radical scavenging property (NAC) to prevent postoperative liver dysfunction in these patients, thus affecting overall clinical outcomes.
Methods: A single-center, prospective, randomized, double-blinded interventional study of 60 patients divided into two groups of 30 each.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!